THE DEAL, AT A GLANCE
1/4 reviewedVinci Pharmaceuticals Inc
Vinci Pharmaceuticals Inc
Vinci develops EPIPLANT, a needle-free way to deliver medicine to the retina for eye diseases.
Vinci Pharmaceuticals Inc raised Series A, announced 2026-10-0801What it doesVinci develops EPIPLANT, a needle-free way to deliver medicine to the retina for eye diseases.Source-grounded · automated review · Explore ↗
Checked 2026-10-08 · Review due 2026-10-15
Read supporting source ↗Our proprietary solution is EPIPLANT™,…
02What happenedVinci Pharmaceuticals Inc raised Series A, announced 2026-10-08From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersVinci Pharmaceuticals Inc is a Monmouth County, New Jersey Series A issuer with a recorded $0M round and a company-record financing description of more than $8 million…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
Vinci Pharmaceuticals Inc · Financing Record
Explore source-linked visual explanations for Vinci Pharmaceuticals Inc. Unsupported claims are withheld while source review continues.
Record 13660 · Recorded date: 2026-10-08
Explore company records →